调节 polo 样激酶 1 作为癌症化学预防的一种手段。
Modulating polo-like kinase 1 as a means for cancer chemoprevention.
机构信息
Department of Dermatology, University of Wisconsin, 1300 University Avenue, Medical Science Center, Room 423, Madison, Wisconsin 53706, USA.
出版信息
Pharm Res. 2010 Jun;27(6):989-98. doi: 10.1007/s11095-010-0051-8. Epub 2010 Jan 27.
Abstract
Naturally occurring agents have always been appreciated for their medicinal value for both their chemopreventive and therapeutic effects against cancer. In fact, the majority of the drugs we use today, including the anti-cancer agents, were originally derived from natural compounds, either in their native form or modified to enhance their bioavailability or specificity. It is believed that for maximum effectiveness, it will useful to design novel target-based agents for chemoprevention as well as the treatment of cancer. Recent studies have shown that the serine/threonine kinase polo-like kinase (Plk) 1 is widely overexpressed in a variety of cancers and is being increasingly appreciated as a target for cancer management. Additionally, several chemopreventive agents have been shown to inhibit Plk1 in cancer cells. In this review, we will discuss if Plk1 could also be a target for designing novel strategies for cancer chemoprevention.
摘要
天然产物因其对癌症的化学预防和治疗作用而一直受到重视。事实上，我们今天使用的大多数药物，包括抗癌药物，最初都是从天然化合物中提取的，无论是以其天然形式还是经过修饰以提高其生物利用度或特异性。人们认为，为了达到最大的效果，设计针对化学预防和癌症治疗的新型基于靶点的药物将是有用的。最近的研究表明，丝氨酸/苏氨酸激酶 polo 样激酶（Plk）1 在多种癌症中广泛过表达，并且作为癌症管理的靶点越来越受到重视。此外，已经有几种化学预防剂被证明可以抑制癌细胞中的 Plk1。在这篇综述中，我们将讨论 Plk1 是否也可以作为设计癌症化学预防新策略的靶点。
相似文献
1
Modulating polo-like kinase 1 as a means for cancer chemoprevention.调节 polo 样激酶 1 作为癌症化学预防的一种手段。
Pharm Res. 2010 Jun;27(6):989-98. doi: 10.1007/s11095-010-0051-8. Epub 2010 Jan 27.
2
Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.靶向Plk1进行抗癌治疗的最新进展与新策略
Trends Pharmacol Sci. 2015 Dec;36(12):858-877. doi: 10.1016/j.tips.2015.08.013. Epub 2015 Oct 17.
3
Polo-like kinase (Plk) 1 as a target for prostate cancer management.Polo样激酶（Plk）1作为前列腺癌治疗的靶点。
IUBMB Life. 2005 Oct;57(10):677-82. doi: 10.1080/15216540500305910.
4
Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.增强polo框结构域结合肽对polo样激酶1的选择性
Bioorg Med Chem. 2017 Oct 1;25(19):5041-5049. doi: 10.1016/j.bmc.2017.02.063. Epub 2017 Feb 28.
5
Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.通过阻断polo框结构域依赖性蛋白质-蛋白质相互作用来抑制polo样激酶1。
Chem Biol. 2008 May;15(5):459-66. doi: 10.1016/j.chembiol.2008.03.013.
6
Polo-like kinases inhibitors. polo 样激酶抑制剂。
Curr Med Chem. 2012;19(23):3937-48. doi: 10.2174/092986712802002455.
7
Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy.靶向 Polo-like kinase 1 治疗癌症的分子和酶信息学研究进展。
Semin Cancer Biol. 2019 Jun;56:47-55. doi: 10.1016/j.semcancer.2017.11.004. Epub 2017 Nov 6.
8
Developing polo-like kinase 1 inhibitors.开发类 polo 样激酶 1 抑制剂。
Future Med Chem. 2020 May;12(10):869-871. doi: 10.4155/fmc-2020-0055. Epub 2020 Apr 1.
9
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present).聚脯氨酸激酶（PLK）抑制剂的研究进展：专利分析（2018 年至今）。
Expert Opin Ther Pat. 2024 Sep;34(9):789-806. doi: 10.1080/13543776.2024.2379924. Epub 2024 Jul 15.
10
Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.含联苯骨架的小分子、非肽类、非 ATP 竞争型 polo 样激酶 1（Plk1）抑制剂。
Bioorg Med Chem. 2013 Feb 1;21(3):608-17. doi: 10.1016/j.bmc.2012.11.054. Epub 2012 Dec 11.
引用本文的文献
1
Polo-like kinase 1 is involved in apoptosis, invasion, and metastasis of pancreatic ductal adenocarcinoma.Polo样激酶1参与胰腺导管腺癌的凋亡、侵袭和转移。
Transl Cancer Res. 2020 Nov;9(11):6672-6682. doi: 10.21037/tcr-20-1019.
2
Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer.模拟 Polo 样激酶在小鼠中的功能及其作为癌症靶点的应用，特别关注卵巢癌。
Cells. 2021 May 12;10(5):1176. doi: 10.3390/cells10051176.
3
The role of Anaphase Promoting Complex activation, inhibition and substrates in cancer development and progression.有丝分裂后期促进复合物的激活、抑制及其在癌症发生和发展中的底物作用。
Aging (Albany NY). 2020 Aug 15;12(15):15818-15855. doi: 10.18632/aging.103792.
4
Activating the Anaphase Promoting Complex to Enhance Genomic Stability and Prolong Lifespan.激活后期促进复合物以增强基因组稳定性和延长寿命。
Int J Mol Sci. 2018 Jun 27;19(7):1888. doi: 10.3390/ijms19071888.
5
Volasertib Enhances Sensitivity to TRAIL in Renal Carcinoma Caki Cells through Downregulation of c-FLIP Expression.伏拉西布通过下调 c-FLIP 表达增强肾癌细胞 Caki 对 TRAIL 的敏感性。
Int J Mol Sci. 2017 Nov 29;18(12):2568. doi: 10.3390/ijms18122568.
6
PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis.与PLK1相关的微小RNA与小儿髓母细胞瘤的预后相关。
Childs Nerv Syst. 2017 Apr;33(4):609-615. doi: 10.1007/s00381-017-3366-5. Epub 2017 Mar 10.
7
RNAi-mediated knockdown of MCM7 gene on CML cells and its therapeutic potential for leukemia.RNA干扰介导的MCM7基因敲低对慢性粒细胞白血病细胞的作用及其对白血病的治疗潜力。
Med Oncol. 2017 Feb;34(2):21. doi: 10.1007/s12032-016-0878-x. Epub 2017 Jan 5.
8
The Catalytic Subunit of DNA-Dependent Protein Kinase Coordinates with Polo-Like Kinase 1 to Facilitate Mitotic Entry.DNA依赖蛋白激酶的催化亚基与Polo样激酶1协同作用以促进有丝分裂进入。
Neoplasia. 2015 Apr;17(4):329-38. doi: 10.1016/j.neo.2015.02.004.
9
Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors.用有丝分裂激酶 1 抑制剂作为单一药物和联合组蛋白去乙酰化酶抑制剂靶向前列腺癌细胞系。
FASEB J. 2013 Oct;27(10):4279-93. doi: 10.1096/fj.12-222893. Epub 2013 Jul 24.
10
Inhibition of polo-like kinase 1 induces cell cycle arrest and sensitizes glioblastoma cells to ionizing radiation.抑制 Polo 样激酶 1 诱导细胞周期停滞并增强脑胶质瘤细胞对电离辐射的敏感性。
Cancer Biother Radiopharm. 2013 Sep;28(7):516-22. doi: 10.1089/cbr.2012.1415. Epub 2013 May 28.
本文引用的文献
1
Activation of ATM-dependent DNA damage signal pathway by a histone deacetylase inhibitor, trichostatin A.组蛋白去乙酰化酶抑制剂曲古抑菌素 A 激活 ATM 依赖的 DNA 损伤信号通路。
Cancer Res Treat. 2007 Sep;39(3):125-30. doi: 10.4143/crt.2007.39.3.125. Epub 2007 Sep 30.
2
Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.polo样激酶1特异性抑制剂GSK461364A具有明显的浓度依赖性效应，包括对细胞凋亡的不同影响。
Cancer Res. 2009 Sep 1;69(17):6969-77. doi: 10.1158/0008-5472.CAN-09-0945. Epub 2009 Aug 18.
3
Apoptosis and cell cycle arrest of human colorectal cancer cell line HT-29 induced by vanillin.香草醛诱导人结肠癌细胞系HT-29的凋亡及细胞周期阻滞
Cancer Epidemiol. 2009 Aug;33(2):155-60. doi: 10.1016/j.canep.2009.06.003. Epub 2009 Jul 3.
4
Polo-like kinase 1 (Plk1) in non-melanoma skin cancers.非黑色素瘤皮肤癌中的Polo样激酶1（Plk1）
Cell Cycle. 2009 Sep 1;8(17):2697-702. doi: 10.4161/cc.8.17.9413. Epub 2009 Sep 2.
5
Cell cycle kinases as therapeutic targets for cancer.细胞周期激酶作为癌症的治疗靶点。
Nat Rev Drug Discov. 2009 Jul;8(7):547-66. doi: 10.1038/nrd2907.
6
The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies.染料木黄酮苷元对癌症及癌症风险的影响：一项关于体外、临床前及临床研究的综述
Nutr Rev. 2009 Jul;67(7):398-415. doi: 10.1111/j.1753-4887.2009.00213.x.
7
Anti-tumor activity of noble indirubin derivatives in human solid tumor models in vitro.新型靛玉红衍生物在人实体瘤体外模型中的抗肿瘤活性
Arch Pharm Res. 2009 Jun;32(6):915-22. doi: 10.1007/s12272-009-1614-2. Epub 2009 Jun 26.
8
Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells.通过慢病毒短发夹RNA（shRNA）或小分子抑制剂对Polo样激酶（Plk）1进行靶向敲除，可导致人黑色素瘤细胞发生有丝分裂灾难并诱导细胞凋亡。
J Invest Dermatol. 2009 Dec;129(12):2843-53. doi: 10.1038/jid.2009.172. Epub 2009 Jun 25.
9
Organization, evolution, and expression analysis of the biosynthetic gene cluster for scytonemin, a cyanobacterial UV-absorbing pigment.蓝藻紫外线吸收色素藻青素生物合成基因簇的组织、进化及表达分析
Appl Environ Microbiol. 2009 Jul;75(14):4861-9. doi: 10.1128/AEM.02508-08. Epub 2009 May 29.
10
Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.在肿瘤学临床前和早期临床开发中的波罗样激酶（PLK）抑制剂
Oncologist. 2009 Jun;14(6):559-70. doi: 10.1634/theoncologist.2009-0010. Epub 2009 May 27.
Zotero 插件